Board of Directors

Chair
Kapil Dhingra, M.B.B.S.
Chair
Kapil Dhingra, M.B.B.S.
Kapil Dhingra, M.B.B.S.
Kapil Dhingra, M.B.B.S. is chair of the LAVA Therapeutics board of directors. Dr. Dhingra is a medical oncologist and a physician-scientist with a proven track record in academic research, patient care and drug development. He served as vice president, head of the oncology disease biology leadership team and head of oncology clinical development at Hoffmann-La Roche (“Roche”), during which he led numerous drug approvals, including Herceptin®, Tarceva® and Avastin®. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. Dr. Dhingra has served as a faculty member at The University of Texas M.D. Anderson Cancer Center, Indiana University School of Medicine and Memorial Sloan Kettering Cancer Center. Dr. Dhingra is currently a member of the boards of directors/supervisors of Black Diamond Therapeutics, Inc., Replimune, Inc., Inc., Autolus Therapeutics plc, Median Technologies, Servier, Curie Therapeutics and Kirilys Therapeutics. He previously served on the boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, Epitherapeutics, Advanced Accelerator Applications, Exosome Diagnostics and Five Prime. He is a member of the NCI Experimental Therapeutics Panel. Dr. Dhingra founded KAPital Consulting, LLC in 2008, a company dedicated to helping biotechnology, pharmaceutical and diagnostic companies realize the clinical and commercial advances in oncology. Dr. Dhingra obtained his bachelor of medicine-bachelor of surgery degree from the All India Institute of Medical Sciences in New Delhi, India. He completed his residency in internal medicine at Lincoln Medical and Mental Health Center, New York Medical College and completed his fellowship in hematology and oncology at Emory University School of Medicine in Atlanta.
Chief Executive Officer, Board Director
Steve Hurly, MS.c., M.B.A.
Steve Hurly
Chief Executive Officer, Board Director
Steve Hurly, MS.c., M.B.A.
Steve Hurly
Steve Hurly, MS.c., M.B.A.
Steve Hurly, MS.c., M.B.A. is the chief executive officer and a board director at LAVA Therapeutics. He brings nearly two decades of leadership experience in the life sciences industry. He served as president and chief executive officer of Sesen Bio, a NASDAQ-listed, late-stage oncology firm. Prior he served as the president and chief executive officer of Viventia Bio Inc., a specialty pharmaceutical company acquired by Sesen Bio Inc. in September 2016. Steve has more than 15 years of experience in the investment banking business. He has served on the board of directors of PHusis Therapeutics Inc., a private targeted small molecule therapeutics company, since May 2011. Previously, he was the chief executive officer of Burrill & Co.’s merchant banking division, a finance business for life science companies. He was also the head of the life sciences investment banking practice at Boenning & Scattergood, a securities asset management and investment banking firm. He graduated from Swarthmore College with a bachelor of arts degree in engineering and earned a master of business administration from the University of Chicago.
Director
Nanna Lüneborg, Ph.D.
Nanna Luneborg
Director
Nanna Lüneborg, Ph.D.
Nanna Luneborg
Nanna Lüneborg, Ph.D.
Nanna Lüneborg, Ph.D., has served as one of our supervisory directors since September 2020. She is currently a general partner of Forbion, since September 2021. She has previously been employed in various roles at Novo Holdings A/S since March 2012, including as partner, principal, investment director. She currently serves on the boards of directors of several other privately held companies, including ReViral, NodThera, Epsilon3‑Bio and Stargazer. She has previously served on the boards of publicly traded and privately held companies, including ObsEva, NBE Therapeutics, Inthera, IO Biotech, MinervaX, Pcovery, Inventiva and Orphazyme. Dr. Lüneborg previously served as an associate at Apposite Capital. She received a bachelor of arts degree in physiology and psychology from the University of Oxford, a doctor of philosophy degree in neuroscience from University College London and a master of business administration from the University of Cambridge. We believe that Dr. Lüneborg is qualified to serve on our board of directors due to her experience serving on the board of directors of clinical-stage biotechnology companies, including public companies and her investment experience within the life science industry.
Director
Stefan Luzi, M.Sc., M.Phil., Ph.D.
Stefan Luzi
Director
Stefan Luzi, M.Sc., M.Phil., Ph.D.
Stefan Luzi
Stefan Luzi, M.Sc., M.Phil., Ph.D.
Stefan Luzi, Ph.D. joined Gilde Healthcare in 2015. He focuses on venture and growth capital investments in the biopharmaceutical sector. He led several investments and currently represents Gilde on the boards of LAVA Therapeutics B.V., Amphista Therapeutics Ltd. and Lumicks B.V. Prior to joining Gilde, Dr. Luzi worked at Merck KGaA where he completed international assignments in the global business intelligence and M ventures divisions. Dr. Luzi received a bachelor of science degree in biology and master of science degree in biotechnology from the Swiss Federal Institute of Technology Zurich (ETH) and a master of philosophy degree in bioscience enterprise from the University of Cambridge. He completed his doctor of philosophy degree with Nobel Laureate Sir Gregory Winter at the MRC laboratory of molecular biology in Cambridge, where he developed a bicyclic peptide-based drug discovery platform.
Director
Guido Magni, M.D., Ph.D.
Guido_Magni
Director
Guido Magni, M.D., Ph.D.
Guido_Magni
Guido Magni, M.D., Ph.D.
Guido Magni, M.D., Ph.D., is a partner with Versant Ventures. He brings deep experience in drug development from multiple accomplishments at leading global pharmaceutical companies including Roche and Wyeth. Dr. Magni held the position of global head of the medical science department at Roche for 12 years and built a track record that includes the approval of 15 new drugs across various therapeutic areas during this time, including blockbuster products Cellcept, Pegasys, Mabthera, Xeloda, Herceptin, Tamiflu and Tarceva. Dr. Magni brings this critical expertise to Versant portfolio companies by providing guidance on their clinical and regulatory strategies.
Director
Joël Jean-Mairet, Ph.D.
Joel Jean Mariet
Director
Joël Jean-Mairet, Ph.D.
Joel Jean Mariet
Joël Jean-Mairet, Ph.D.
Joël Jean-Mairet, Ph.D. is managing partner and co-founder of Ysios Capital. Previously, he co-founded Glycart Biotechnology in 2001 and was its chief executive officer until it was successfully sold to F. Hoffmann La-Roche four years later. Glycart Biotechnology was the originator of the anti-CD20 antibody – obinituzumab/Gazyva®, the first breakthrough designated drug approved by the FDA for B-CLL. He holds a master of science degree in biotechnology and a doctor of philosophy degree from the Swiss Federal Institute of Technology (ETH) in Zurich. Dr. Jean-Mairet is currently on the boards of directors of Adcendo, Ona Therapeutics, SpliceBio, executive chair of Inbiomotion and board observer at AM-Pharma. He has previously served as chair of the board of Cellerix/Tigenix (now Takeda), board member of Aura Biosciences (Nasdaq: AURA), Sanifit Therapeutics (now Vifor Pharma) and board observer at Biovex (now Amgen). Dr. Jean-Mairet has earned numerous awards, including the Wall Street Journal’s Europe Innovation Award in 2001.  
Director
Erik van den Berg, M.Sc., M.B.A.
Erik van dan Berg
Director
Erik van den Berg, M.Sc., M.B.A.
Erik van dan Berg
Erik van den Berg, M.Sc., M.B.A.
Erik van den Berg, M.Sc., M.B.A. is a board director at LAVA Therapeutics. Mr. Van den Berg has more than 25 years of experience in the pharmaceutical industry. He currently serves as the chief executive officer of AM-Pharma as well as a board member at Lead Pharma, Step Pharma and, previously, the Dutch biotechnology organization. Before joining AM-Pharma, Mr. Van den Berg served as a senior executive at Organon (Merck) where he was responsible for leading the company’s global biotechnology business development. He has executed more than 20 transactions and partnerships, including a $600 million alliance with Pfizer, a $290 million partnership with Kyowa Kirin and raised close to €500 million in equity and debt financing for biotechnology companies from seed through IPO. Mr. Van den Berg earned a master of science degree in chemistry from the University of Utrecht, The Netherlands, and a master of business administration from Manchester Business School, the United Kingdom, both with honors.
Director
Karen Wilson, C.P.A.
Karen Wilson
Director
Karen Wilson, C.P.A.
Karen Wilson
Karen Wilson, C.P.A.
Karen Wilson, C.P.A. has served as one of the LAVA Therapeutics supervisory directors since March 2021. She currently serves on the board of directors of Angion Biomedica, Connect Biopharma and Vaxart, Inc. Ms. Wilson served as senior vice president of finance at Jazz Pharmaceuticals plc until September 2020 after serving as vice president of finance and principal accounting officer. Prior to joining Jazz Pharmaceuticals in February 2011, Ms. Wilson served as vice president of finance and principal accounting officer at PDL BioPharma, Inc. She also previously served as a principal at the consulting firm of Wilson Crisler LLC, chief financial officer of ViroLogic, Inc., chief financial officer and vice president of operations for Novare Surgical Systems, Inc., and as a consultant and auditor for Deloitte & Touche LLP. Ms. Wilson is a certified public accountant and received a bachelor of science degree in business from the University of California, Berkeley.